VLA 0.00% $1.75 viralytics limited

ESMO 2016 - clinical trial updates

  1. 236 Posts.
    lightbulb Created with Sketch. 9
    All of the latest trial updates are listed for presentation at ESMO 2016  in October.

    9th Oct
    1157TiP - Phase Ib study of intratumoral oncolytic coxsackievirus A21 (CVA21) and pembrolizumab in subjects with advanced melanoma

    1104TiP - Intravenous coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: Phase Ib KEYNOTE 200 study

    10th Oct
    1051PD - The MITCI (phase 1b) study: A novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma

    1054PD - Phase I/II CANON study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21

    It should be a very exciting time.   Only 2 more months to wait .....


arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.